SINO BIOPHARM: 2024 ANNUAL REPORT

SINO BIOPHARM announced its mid-year results for 2024, achieving revenue of 28.87 billion yuan, a year-on-year increase of 10.2%; gross profit of 23.53 billion yuan, a year-on-year increase of 10.9%; and net profit attributable to Shareholders of 3.4 billion yuan. The Board of Directors declared a mid-year dividend of 0.02 yuan per share for 2024, totaling a payout of 0.506 billion yuan.The company's financial position remains robust, with total Assets reaching 65.41 billion yuan and total liabilities at 22.63 billion yuan as of the end of the reporting period. Cash and Banks balance is 9.57 billion yuan, with interest-bearing bank loans of 9.58 billion yuan, maintaining a balanced financial structure. During the period, share repurchase and cancellation were completed with an investment of 22.38 million...Show More

SINO BIOPHARM announced its mid-year results for 2024, achieving revenue of 28.87 billion yuan, a year-on-year increase of 10.2%; gross profit of 23.53 billion yuan, a year-on-year increase of 10.9%; and net profit attributable to Shareholders of 3.4 billion yuan. The Board of Directors declared a mid-year dividend of 0.02 yuan per share for 2024, totaling a payout of 0.506 billion yuan.The company's financial position remains robust, with total Assets reaching 65.41 billion yuan and total liabilities at 22.63 billion yuan as of the end of the reporting period. Cash and Banks balance is 9.57 billion yuan, with interest-bearing bank loans of 9.58 billion yuan, maintaining a balanced financial structure. During the period, share repurchase and cancellation were completed with an investment of 22.38 million yuan, along with the implementation of a share-based payment arrangement valued at 53.43 million yuan.The company recorded foreign exchange gains of 0.422 billion yuan and gains from fair value changes of financial assets of 33.22 million yuan during the period. Management indicated a continuous focus on biopharmaceutical R&D, manufacturing, and Business sales, further expanding market share and enhancing operational efficiency through key subsidiaries such as CSPC PHARMA, Nanjing CSPC, and Jiangsu Lianyungang Port.